A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program. Risk of recurrent ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Research found fecal microbiota transplantation (FMT) to be an optimal cost-effective treatment strategy for first and subsequent recurrent Clostridioides difficile infection (CDI), challenging ...

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...

Please provide your email address to receive an email when new articles are posted on . “C. difficile is a major problem for people in the United States; it is the most common health care-associated ...

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

NICE commissioned an external assessment centre (EAC) to review the evidence. This section summarises that review. Full details of all the evidence are in the project documents on the NICE website.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Two ...

WASHINGTON -- Extended follow-up of a phase III trial demonstrated continued benefit for an investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infections.

The randomised controlled trial (RCT) evidence showed that faecal microbiota transplant (FMT) after pretreatment antibiotics was significantly better at resolving a recurrent Clostridioides difficile ...